Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction
暂无分享,去创建一个
Akshay S. Desai | S. Solomon | M. Pfeffer | S. Yusuf | A. Desai | K. Swedberg | S. Pocock | C. Granger | J. McMurray | N. Bello | B. Claggett | P. Finn
[1] J. Cleland,et al. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. , 1998, European heart journal.
[2] D. DeMets,et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.
[3] Karl Swedberg,et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.
[4] Hilary K. Wall,et al. Costs of heart failure-related hospitalizations in patients aged 18 to 64 years. , 2010, The American journal of managed care.
[5] S. Schneeweiss,et al. Repeated hospitalizations predict mortality in the community population with heart failure. , 2007, American heart journal.
[6] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[7] H. Krumholz,et al. Spectrum of heart failure in older patients: results from the National Heart Failure project. , 2002, American heart journal.
[8] H. Tsutsui. [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[9] George A Mensah,et al. Heart failure-related hospitalization in the U.S., 1979 to 2004. , 2008, Journal of the American College of Cardiology.
[10] M. Pfeffer,et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.
[11] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[12] T. Therneau,et al. Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.
[13] A. Jha,et al. Who Has Higher Readmission Rates for Heart Failure, and Why?: Implications for Efforts to Improve Care Using Financial Incentives , 2011, Circulation. Cardiovascular quality and outcomes.
[14] Ulf Dahlström,et al. Frequent non‐cardiac comorbidities in patients with chronic heart failure , 2005, European journal of heart failure.
[15] Salim Yusuf,et al. Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.
[16] Albert W Wu,et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.
[17] C. Lang,et al. Non-cardiac comorbidities in chronic heart failure , 2006, Heart.
[18] C. O'connor,et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.
[19] Akshay S. Desai,et al. Heart failure with preserved ejection fraction: time for a new approach? , 2013, Journal of the American College of Cardiology.
[20] Sanjiv J Shah,et al. Heart failure with preserved ejection fraction: treat now by treating comorbidities. , 2008, JAMA.
[21] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[22] V. Roger,et al. Lifetime Costs of Medical Care After Heart Failure Diagnosis , 2011, Circulation. Cardiovascular quality and outcomes.
[23] D G Altman,et al. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. , 1994, Statistics in medicine.
[24] D. Redelmeier,et al. The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.
[25] Stefan Störk,et al. Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure: The Interdisciplinary Network for Heart Failure (INH) Study , 2012, Circulation. Heart failure.
[26] S. Normand,et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission , 2009, Circulation. Cardiovascular quality and outcomes.
[27] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[28] S. Janower. Rosuvastatin in older patients with systolic heart failure. , 2007 .
[29] Harlan M. Krumholz,et al. Recent National Trends in Readmission Rates After Heart Failure Hospitalization , 2010, Circulation. Heart failure.
[30] Sheila Roman,et al. Public reporting and pay for performance in hospital quality improvement. , 2007, The New England journal of medicine.
[31] M. Clearfield. Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.
[32] P. Austin,et al. Improved Outcomes With Early Collaborative Care of Ambulatory Heart Failure Patients Discharged From the Emergency Department , 2010, Circulation.
[33] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[34] K. Swedberg,et al. Risk following hospitalization in stable chronic systolic heart failure , 2013, European journal of heart failure.